Raphael Pharmaceutical Announces Filing of Provisional Patent Application for the Treatment of Neutrophil-Dominant Autoimmune Diseases, Including Rheumatoid Arthritis (RA)
Raphael Pharmaceutical Announces Positive Proof-of-Concept Clinical Study Results for the Company's Cannabinoid-Based Formula for the Treatment of Rheumatoid Arthritis
Raphael Pharmaceutical Issues Letter to Shareholders